Drugs / NRX 195183
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02749708 | Jan 2017 → Aug 2018 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00234169 | Oct 2005 → Jan 2008 | plasma cell myeloma | Peter MacCallum Cancer Centre, Australia | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00670150 | May → Aug 2010 | acute promyelocytic leukemia | University of Southern California | Withdrawn | No outcome recorded |
| Phase 2 | NCT00675870 | Apr 2008 → Apr 2010 | acute promyelocytic leukemia | NuRx Pharmaceuticals, Inc. | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NRX 195183 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00675870 ↗ |
| Known as | AGN 195183 | ChEMBL registry synonym — accepted as the source's own label CHEMBL107430 ↗ |
| Known as | IRX5183 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02749708 ↗ |
| Known as | VTP-5183 | ChEMBL registry synonym — accepted as the source's own label CHEMBL107430 ↗ |
| Known as | VTP195183 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00234169 ↗ |
| Action | Activate | “a novel retinoic acid receptor α agonist” PMID 33194741 ↗ Oct 2020 |
| Modality | Small molecule | — CHEMBL107430 ↗ |
| Route | Oral | “VTP195183: 60mg/m2 orally daily” NCT00234169 ↗ |
| Target | RARA | “a novel retinoic acid receptor α agonist” PMID 33194741 ↗ Oct 2020 |